Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317

PURPOSE: Patients with advanced papillary renal cell cancer (pRCC) have poor survival after systemic therapy; the reported median survival time is 7 to 17 months. In this trial, we evaluated the efficacy of erlotinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor in patie...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Gordon, Michael S., Hussey, Michael, Nagle, Raymond B., Lara, Primo N., Mack, Philip C., Dutcher, Janice, Samlowski, Wolfram, Clark, Joseph I., Quinn, David I., Pan, Chong-Xian, Crawford, David
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2009
Assuntos:
Original Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2793000/
https://ncbi.nlm.nih.gov/pubmed/19884559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.18.8821
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares